NASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Price, News & Analysis $38.41 -0.20 (-0.52%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$37.86 -0.55 (-1.43%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About IDEAYA Biosciences Stock (NASDAQ:IDYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IDEAYA Biosciences alerts:Sign Up Key Stats Today's Range$38.15▼$39.2550-Day Range$35.00▼$42.4852-Week Range$25.27▼$42.68Volume2.49 million shsAverage Volume641,897 shsMarket Capitalization$3.37 billionP/E RatioN/ADividend YieldN/APrice Target$52.69Consensus RatingModerate Buy Company Overview IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for cancer. The company uses insights from tumor genetics and synthetic lethality—the targeting of vulnerabilities created by specific genetic alterations—to identify therapies intended for molecularly defined patient populations. IDEAYA’s investigational pipeline includes darovasertib (IDE196), a protein kinase C inhibitor being studied in genetically defined cancers, including metastatic uveal melanoma associated with GNAQ or GNA11 mutations. The company is also developing IDE397, an inhibitor of methionine adenosyltransferase 2A (MAT2A) designed to target tumors with MTAP gene deletions. Its research and development activities include discovery programs, clinical trials, and collaborations with pharmaceutical and biotechnology partners. Founded in 2015, IDEAYA is headquartered in South San Francisco, California, and develops therapies for patients in international clinical and commercial markets through its research programs and industry collaborations. The company is led by Yuval Cohen, Ph.D., who serves as chief executive officer and has been associated with IDEAYA since its founding.AI Generated. May Contain Errors. Read More IDEAYA Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreIDYA MarketRank™: IDEAYA Biosciences scored higher than 64% of companies evaluated by MarketBeat, and ranked 379th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialIDEAYA Biosciences has a consensus price target of $52.69, representing about 37.2% upside from its current price of $38.41.Amount of Analyst CoverageIDEAYA Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IDEAYA Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for IDEAYA Biosciences are expected to grow in the coming year, from ($4.38) to ($4.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -19.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -19.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 3.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IDEAYA Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.07% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 12.21, which indicates bearish sentiment.Change versus previous monthShort interest in IDEAYA Biosciences has recently decreased by 2.83%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.85 News SentimentIDEAYA Biosciences has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for IDEAYA Biosciences this week, compared to 5 articles on an average week.MarketBeat Follows2 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $382,096.00 in company stock.Percentage Held by Insiders4.70% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IDEAYA Biosciences' insider trading history. Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDYA Stock News HeadlinesIDEAYA Biosciences, Inc. (IDYA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comCiti Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)September 12, 2026 | theglobeandmail.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Medicus Pharma Ltd (MDCX)September 10, 2026 | theglobeandmail.comIDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 10, 2026 | seekingalpha.comIDEAYA Biosciences, Inc.: IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as ...September 9, 2026 | finanznachrichten.deIdeaya Biosciences, Servier Dose First Patient in Phase-3 Primary Uveal Melanoma TrialSeptember 9, 2026 | finance.yahoo.comIDEAYA And Servier Dose First Patient In Global Phase 3 OptimUM-11 Trial For Uveal MelanomaSeptember 9, 2026 | rttnews.comSee More Headlines IDYA Stock Analysis - Frequently Asked Questions How have IDYA shares performed this year? IDEAYA Biosciences' stock was trading at $34.57 on January 1st, 2026. Since then, IDYA shares have increased by 11.1% and is now trading at $38.41. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) posted its earnings results on Tuesday, August, 4th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.06) by $0.16. IDEAYA Biosciences's revenue was up 8800.0% on a year-over-year basis. When did IDEAYA Biosciences IPO? IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO. Who are IDEAYA Biosciences' major shareholders? IDEAYA Biosciences' top institutional shareholders include BlackRock Inc. (10.12%), Jupiter Topco LLC (9.77%), Bank of America Corp DE (1.17%) and Walleye Capital LLC (0.44%). Insiders that own company stock include Yujiro S Hata, Jeffrey Stein, Briseno Andres Ruiz, Jason Throne and Michael Anthony White. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings8/04/2026Today9/19/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IDYA's financial health is in the Green zone, according to TradeSmith. IDYA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IDYA CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees145Year Founded2015Price Target and Rating Average Price Target for IDEAYA Biosciences$52.69 High Price Target$79.00 Low Price Target$30.00 Potential Upside/Downside+37.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$113.70 million Net Margins-75.93% Pretax Margin-74.75% Return on Equity-16.73% Return on Assets-15.34% Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio10.45 Sales & Book Value Annual Sales$218.71 million Price / Sales15.43 Cash FlowN/A Price / Cash FlowN/A Book Value$11.67 per share Price / Book3.29Miscellaneous Outstanding Shares87,860,000Free Float83,732,000Market Cap$3.37 billion OptionableOptionable Beta-0.07 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:IDYA) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
